Cybin Stock (NASDAQ:HELP)

Financials Chart Transcripts

Previous Close

$5.89

52W Range

$3.76 - $9.12

50D Avg

$4.97

200D Avg

$5.98

Market Cap

$301.72M

Avg Vol (3M)

$1.20M

Beta

0.62

Div Yield

-

HELP Company Profile

Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

50

IPO Date

Sep 13, 2019

Website

HELP Performance

HELP Financial Summary

	Mar 25	Mar 24	Mar 23
Revenue	-	-	-
Operating Income	$-143.15M	$-78.84M	$-51.52M
Net Income	$-113.14M	$-78.08M	$-40.04M
EBITDA	$-142.67M	$-78.58M	$-51.28M
Basic EPS	$-0.61	$-9.50	$-0.22
Diluted EPS	$-0.61	$-9.41	$-0.22

Fiscal year ends in Mar 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Nov 13, 25 | 8:00 AM

Q3 22Feb 10, 22 | 8:30 AM

Q2 22Nov 15, 21 | 4:30 PM